Drug news
FDA approves Rasuvo SC for Rheumatoid Arthritis - Medac Pharma
The FDA has approved Rasuvo (subcutaneous injectable methotrexate), from Medac Pharma, delivered in an auto-injector for Rheumatoid Arthritis (RA), polyarticular-course juvenile idiopathic Arthritis (pJIA) and Psoriasis. Rasuvo will be available in 10 dosage strengths, ranging from 7.5 mg to 30 mg in 2.5 mg increments and will be launched in the US.